Travere Therapeutics recap cites FILSPARI growth and $489M cash
Travere Therapeutics said FILSPARI adoption is driving growth in IgA nephropathy and FSGS, while it advances pegtibatinase and civorebrutinib. The company also reported roughly $489M cash and granted 56,220 RSUs to 16 new hires.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.